ArticleInternational urology and nephrology2026
Concurrent extension of bladder cancer to the intramural ureter and prostatic urethra increases the risk of urethral cancer in patients undergoing radical cystectomy.
Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeBladder cancer extension to the prostatic urethra is a well-known risk factor for urethral recurrence. This study investigated whether concurrent involvement of the intramural ureter, in addition to the prostatic urethra, further increases the urethral cancer risk.
methodsWe retrospectively analyzed 316 male patients who underwent radical cystectomy for bladder cancer between 2002 and 2020. We assessed the prevalence of tumor extension to the prostatic urethra and intramural ureter and evaluated its association with synchronous and metachronous urethral cancer. Synchronous urethral cancer was defined as cancer detected in the pendulous, bulbar, or membranous urethra, whereas metachronous urethral cancer was defined as cancer developing in the remnant urethra. Logistic regression analyses were performed to identify risk factors for urethral cancer.
resultsThe median follow-up duration was 61 months. Among the 316 patients, 148 underwent prophylactic urethrectomy during cystectomy, and 168 did not. Urethral cancer occurred in 12 (3.8%): 8 (5.4%) had synchronous urethral cancer, and 4 (2.4%) developed metachronous urethral cancer. In multivariate analysis, the odds ratios for urethral cancer were 3.91 (95% confidence interval [CI], 0.84-18.20; p = 0.082) for cancer extension limited to the prostatic urethra and 12.60 (95% CI 2.75-57.60; p = 0.001) for cancer extension to the prostatic urethra and intramural ureter, compared with no cancer extension to the prostatic urethra.
conclusionTwo distinct patterns of prostatic urethral involvement exist. Bladder cancer extending to the prostatic urethra and intramural ureter was associated with an increased risk of synchronous and metachronous urethral cancers.
Indexed as
Identifiers
42799953What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.